Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin

(2013) Shivani Srivastava et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

(2013) Ryan M. Stephenson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Intraindividual long term stability and response corridors of cytokines in healthy volunteers detected by a standardized whole-blood culture system for bed-side application

(2012) Silke C Mueller et al.   BMC Medical Research Methodology

IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients

(2012) B. Schilling et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Regulation of inflammasome signaling

(2012) Vijay A K Rathinam et al.   NATURE IMMUNOLOGY

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

(2012) Mélanie Bruchard et al.   NATURE MEDICINE

Macrophages Help NK Cells to Attack Tumor Cells by Stimulatory NKG2D Ligand but Protect Themselves from NK Killing by Inhibitory Ligand Qa-1

(2012) Zhixia Zhou et al.   PLoS One

Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28

(2011) J. S. Pufnock et al.   BLOOD

B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors

(2011) Tomonori Kaifu et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

(2011) H. Lu et al.   CLINICAL CANCER RESEARCH

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma

(2011) Maria Wysocka et al.   LEUKEMIA & LYMPHOMA

Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075

(2010) S. Spranger et al.   JOURNAL OF IMMUNOLOGY

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cutting Edge: NF- B Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression

(2009) F. G. Bauernfeind et al.   JOURNAL OF IMMUNOLOGY

A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition

(2009) Jin Liu et al.   MOLECULAR IMMUNOLOGY

The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis

(2009) Luigi Franchi et al.   NATURE IMMUNOLOGY

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE

Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

(2008) Veit Hornung et al.   NATURE IMMUNOLOGY